Authors' recommendations: There is no evidence that the use of ceritinib increases overall survival in patients with advanced non-small cell lung cancer. Good quality evidence shows that its use, when compared with chemotherapy, would increase progression-free survival and overall response rate as first-line treatment or in patients who previously received crizotinib; being the first indication not approved by ANMAT (Argentina's National Administration of Medicaments, Food and Medical Technology) or other regulatory agencies yet. No studies assessing its efficacy and safety versus crizotinib or other treatment options have been found. There is consensus among the clinical practice guidelines from main international societies on considering ceritinib among the treatment options in those patients with advanced ALK+ non-small cell lung cancer, who show progression after treatment with crizotinib or in case of intolerance to it. The coverage policies from public and private health sponsors consulted cover it for this indication, in some cases only after reaching an agreement on the selling price.

Project Status: Completed

Year Published: 2017

URL for published report: www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)